Breaking News, Promotions & Moves

Atavistik Bio Names Bryan Stuart Chief Executive Officer

Stuart brings more than 25 years of biopharma executive leadership, corporate strategy, and business development experience.

Atavistik Bio, a biotechnology company focused on developing transformative small molecule therapeutics with its AMPS platform, appointed Bryan Stuart as Chief Executive Officer and a director on the company’s board. Stuart will succeed Jeff Goater, a venture partner at The Column Group, who has served as interim CEO of Atavistik Bio since January 2022. Goater will continue to serve as a director on Atavistik Bio’s Board. Stuart was most recently CEO of Fulcrum Therapeutics, where he initiall...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters